The original success of the copyright undeniably revolutionized the pharmaceutical landscape, but placing funds in companies heavily reliant on unbranded versions presents a complex picture. Despite early profits were impressive, the expiration of patents and the rise of less expensive alternatives have diminished sales. Thus, a thorough assessment